Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

Novo Nordisk shares rose as much as 5% following U.S. FDA accelerated approval for its weight-loss drug Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), marking the first GLP-1 therapy cleared for the progressive liver condition. This positive development offers a significant rebound for the drugmaker, which had recently lost over one-third of its market value, though analysts anticipate transitional market exclusivity given rival Eli Lilly's promising MASH data.

Analysis

Novo Nordisk (NVO) shares responded positively, rising as much as 5%, following the U.S. Food and Drug Administration's accelerated approval for its drug Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH). This regulatory milestone establishes Wegovy as the first GLP-1 class therapy for the progressive liver condition, providing a significant boost to the company after it recently shed $70 billion in market value due to a profit warning and CEO change. However, this first-mover advantage is expected to be transient. Key competitor Eli Lilly (LLY) has already published encouraging mid-stage trial data for its own MASH candidate, tirzepatide, leading analysts to forecast that Novo's market exclusivity will be a transitional phase. The approval comes amid a backdrop of intense competition, with existing concerns that Novo Nordisk is losing ground to Eli Lilly and compounded copycat drugs in the broader obesity treatment market.

Key Decisions for Investors

• Investors should view the FDA approval for Wegovy in MASH as a significant, but likely temporary, advantage for Novo Nordisk; the key factor to monitor is the timeline of Eli Lilly's competing product launch.
• The encouraging MASH data from Eli Lilly reinforces its strong competitive posture, suggesting its entry into this market is a matter of when, not if, which could limit the long-term revenue potential for Novo Nordisk's Wegovy in this indication.
• Given the intense rivalry, portfolio allocation within the GLP-1 space should be weighed against the ongoing clinical and regulatory developments from both companies, as market share in the MASH segment remains a critical future catalyst.